How achievable is target HbA1c in insulin-treated type 2 diabetes (T2DM)? A multicentre study of 2025 patients from 8 specialist endocrine practices, including relationship of control to treatment centre and pattern of insulin administration — ASN Events
  1. Schedule
  2. ADS Clinical Poster Session
  3. How achievable is target HbA1c in insulin-treated type 2 diabetes (T2DM)? A multicentre study of 2025 patients from 8 specialist endocrine practices, including relationship of control to treatment centre and pattern of insulin administration

How achievable is target HbA1c in insulin-treated type 2 diabetes (T2DM)? A multicentre study of 2025 patients from 8 specialist endocrine practices, including relationship of control to treatment centre and pattern of insulin administration (#275)

David M Hoffman 1 2 , Anthony M Morrow 1 , David Darnelle 3 , Jerry R Greenfield 1 , Natalie Harrison 4 , Kimberly Cukier 4 , Tien-Ming Hng 1 , N.W Cheung 1 , Greg R Fulcher 1
  1. Endocrinologist, Australian Diabetes Informatics Group (DINGO), Sydney, NSW, Australia
  2. Software 4 Specialists, Sydney, Australia
  3. Endocrinologist, Australian Diabetes Informatics Group (DINGO), Gosford, NSW, Australia
  4. Endocrinologist, Australian Diabetes Informatics Group (DINGO), Geelong, Victoria, Australia

Aim:  (1) To benchmark the level of glycaemic control achieved in patients with T2DM treated in community endocrine practice, comparing insulin-treated and  non-insulin treated patients  (2) To understand how variations in patterns of insulin treatment within and between endocrine practices impact on glycaemic control and achievement of HbA1c target.

Method: Cross sectional study using de-identified data from endocrinologist’s electronic medical record (Audit4 program, Software 4 Specialists, Australia).

Results:

231-Hoffman.jpg

Conclusion: (1) Achievement of target HbA1c < 7 % in insulin-treated T2DM remains an elusive goal even in specialist hands as insulin cannot restore healthier levels of glycaemia observed in the earlier stages of the disease (2) Insulin regimen and dose has little overall impact on glycaemic control (3) Glycaemic control varies significantly between treatment centres but the variation appears to be related to factors other than pattern of insulin administration.